Sylvia L Groth1, Eiyass Albeiruti2, Mariana Nunez3, Roman Fajardo4, Lucie Sharpsten4, Nils Loewen2, Joel S Schuman2, Jeffrey L Goldberg5. 1. Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, California. 2. Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 3. Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, California; Bascom Palmer Eye Institute, University of Miami, Miami, Florida; Shiley Eye Institute, University of California, San Diego, La Jolla, California. 4. Shiley Eye Institute, University of California, San Diego, La Jolla, California. 5. Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, California; Bascom Palmer Eye Institute, University of Miami, Miami, Florida; Shiley Eye Institute, University of California, San Diego, La Jolla, California. Electronic address: eye-chair@stanford.edu.
Abstract
PURPOSE: This study examined whether short-term use of topical nonsteroidal anti-inflammatory drug (NSAID) or steroid therapy affected the efficacy of selective laser trabeculoplasty (SLT). DESIGN: Double-masked, randomized, placebo-controlled, dual-center, multisurgeon trial. PARTICIPANTS: Patients older than 18 years with intraocular pressure (IOP) of more than 18 mmHg for whom the clinician decided SLT was the appropriately indicated therapy were randomized to 1 of 3 groups in a ratio of 1:1:1 as follows: ketorolac 0.5%, prednisolone 1%, or saline tears. METHODS: After SLT, patients randomized into each group were instructed to use an unmarked drop 4 times daily starting the day of SLT and continuing for 4 additional days. The Kruskal-Wallis test and Wilcoxon rank-sum test were used for continuous variables when comparing 2 or 3 treatment groups, respectively. The Fisher exact test was used for categorical variables. MAIN OUTCOME MEASURES: The primary outcome of this study was IOP at 12 weeks. Secondary outcome measures included IOP at 1 and 6 weeks, patient-reported pain, and detectable anterior chamber inflammation. RESULTS:Ninety-six eyes of 85 patients fit inclusion criteria and were enrolled between the 2 sites. The NSAID, steroid, and placebo groups were similar in baseline demographics and baseline IOP (mean, 23.3±3.9 mmHg; P = 0.57). There was no statistically significant difference in IOP decrease among groups at week 6. Both the NSAID and steroid groups showed a statistically significantly greater decrease in IOP at week 12 compared with the placebo group (mean, -6.2±3.1 mmHg, -5.2±2.7 mmHg, and -3±4.3 mmHg, respectively; P = 0.02 [analysis of variance] and P = 0.002 [t test] for NSAID vs. placebo groups; P = 0.02 for steroid vs. placebo groups). CONCLUSIONS: Significantly better IOP reduction at 12 weeks was measured in eyes treated with steroid or NSAID drops after SLT. Short-term postoperative use of NSAID or steroid drops may improve IOP reduction after SLT. Longer-term follow-up studies are indicated. Published by Elsevier Inc.
RCT Entities:
PURPOSE: This study examined whether short-term use of topical nonsteroidal anti-inflammatory drug (NSAID) or steroid therapy affected the efficacy of selective laser trabeculoplasty (SLT). DESIGN: Double-masked, randomized, placebo-controlled, dual-center, multisurgeon trial. PARTICIPANTS: Patients older than 18 years with intraocular pressure (IOP) of more than 18 mmHg for whom the clinician decided SLT was the appropriately indicated therapy were randomized to 1 of 3 groups in a ratio of 1:1:1 as follows: ketorolac 0.5%, prednisolone 1%, or saline tears. METHODS: After SLT, patients randomized into each group were instructed to use an unmarked drop 4 times daily starting the day of SLT and continuing for 4 additional days. The Kruskal-Wallis test and Wilcoxon rank-sum test were used for continuous variables when comparing 2 or 3 treatment groups, respectively. The Fisher exact test was used for categorical variables. MAIN OUTCOME MEASURES: The primary outcome of this study was IOP at 12 weeks. Secondary outcome measures included IOP at 1 and 6 weeks, patient-reported pain, and detectable anterior chamber inflammation. RESULTS: Ninety-six eyes of 85 patients fit inclusion criteria and were enrolled between the 2 sites. The NSAID, steroid, and placebo groups were similar in baseline demographics and baseline IOP (mean, 23.3±3.9 mmHg; P = 0.57). There was no statistically significant difference in IOP decrease among groups at week 6. Both the NSAID and steroid groups showed a statistically significantly greater decrease in IOP at week 12 compared with the placebo group (mean, -6.2±3.1 mmHg, -5.2±2.7 mmHg, and -3±4.3 mmHg, respectively; P = 0.02 [analysis of variance] and P = 0.002 [t test] for NSAID vs. placebo groups; P = 0.02 for steroid vs. placebo groups). CONCLUSIONS: Significantly better IOP reduction at 12 weeks was measured in eyes treated with steroid or NSAID drops after SLT. Short-term postoperative use of NSAID or steroid drops may improve IOP reduction after SLT. Longer-term follow-up studies are indicated. Published by Elsevier Inc.
Authors: Ronald L Rebenitsch; Eric N Brown; Nick R Binder; Aditi Jani; Aaron J Bonham; Rohit Krishna; Kevin Pikey Journal: Ophthalmol Ther Date: 2013-08-31
Authors: Raul E Ruiz-Lozano; Jimena Alamillo-Velazquez; Gustavo Ortiz-Morales; Lucas A Garza-Garza; Manuel E Quiroga-Garza; Carlos Alvarez-Guzman; Alejandro Rodriguez-Garcia Journal: Int Ophthalmol Date: 2022-08-13 Impact factor: 2.029
Authors: Faruque Ghanchi; Rupert Bourne; Susan M Downes; Richard Gale; Christina Rennie; Ian Tapply; Sobha Sivaprasad Journal: Eye (Lond) Date: 2022-01-01 Impact factor: 4.456
Authors: Ricardo Y Abe; Heloísa A Maestrini; Guilherme B Guedes; Marcelo M Nascimento; Camila I Iguma; Hérika Danielle de Miranda Santos; Muna Georges Nasr; Ricarte P Lucena-Junior; Tiago S Prata Journal: Sci Rep Date: 2022-02-04 Impact factor: 4.379